Stereotactic radiofrequency ablation of a variety of liver masses in children

Hetzer, Benjamin; Vogel, Georg-Friedrich; Entenmann, Andreas; Heil, Michel; Schullian, Peter; Putzer, Daniel; Meister, Bernhard; Crazzolara, Roman; Kropshofer, Gabriele; Salvador, Christina; Straub, Simon; Niederwanger, Christian; Cortina, Gérard; Janecke, Andreas; Freund-Unsinn, Karin; Maurer, Kathrin; Schweigmann, Gisela; Oberhuber, Georg; Renz, Oliver; Schneeberger, Stefan; Müller, Thomas; Bale, Reto

doi:10.1080/02656736.2020.1822549

Cited by 13 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, no studies on the e cacy of percutaneous RFA have been conducted in the particular setting of pediatric RHCC. Hetzer et al reported the utility of percutaneous stereotactic RFA for various liver masses in children [39]. Compared to their study, we adopted US-guided RFA, which was convenient and free of radiation.…”

Section: Discussionmentioning

confidence: 99%

Radiofrequency Ablation for Pediatric Recurrent Hepatocellular Carcinoma: A Single-center Experience

Long

Zhou

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: To summarize our single-center experience with percutaneous ultrasound (US)-guided radiofrequency ablation (RFA) for pediatric recurrent hepatocellular carcinoma (RHCC). Methods: From September 2007 to September 2021, patients under 18 who underwent percutaneous US-guided RFA for RHCC were retrospectively enrolled in this study. Local effectiveness, complications, local tumor progression (LTP), progression free survival (PFS), and overall survival (OS) were evaluated. Results: A total of 10 patients (9 male and 1 female; mean age, 11.7±4 years ; age range, 6-17 years) with 15 intrahepatic RHCC lesions were enrolled in this study. Complete ablation (CA) was achieved in 14 out of 15 lesions (93.3%) after the first RFA. During the follow-up (mean, 63.1±18 months; range, 5.3-123.3 months), LTP did not occur. Five patients died including three with tumor progression and one with liver failure. The accumulative one- and three-year PFS rates were 30% and 10%, respectively. The accumulative one- and three-year OS rates were 77.8 % and 44.4%, respectively. Conclusions: Our single-center experience suggests the safety and feasibility of percutaneous US-guided RFA for pediatric RHCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiofrequency Ablation for Pediatric Recurrent Hepatocellular Carcinoma: A Single-center Experience

Long

Zhou

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Percutaneous TA has also been gradually applied in the treatment of pediatric liver neoplasms. Hetzer et al [11] safely deployed stereotactic RFA (11 sessions, 15 lesions) in 10 pediatric patients with liver masses and extrahepatic metastasis, and follow-up imaging studies (median: 55 months, range: 18-129 months) revealed no local or distant recurrence of disease in any patient. Steven et al [13] used RFA to treat five patients with 23 HB metastases in the lungs, liver, or bone and achieved local control in 22 of them (95.6%) at a median follow-up period of 30.1 months (range: 18.9-65.7 months) after RFA.…”

Section: Discussionmentioning

confidence: 99%

“…It has a similar treatment effect to that of open surgery in small liver cancers with the advantage of minimal invasion. At present, some studies have preliminarily discussed the efficacy of TA in the treatment of HB, having observed favorable treatment effects [10][11][12][13][14]. This study sought to determine the differences in treatment effect and safety profiles between TA and OLR in the treatment of recurrent HB and provide evidence of other feasible treatments for children with HB.…”

Section: Introductionmentioning

confidence: 99%

Percutaneous thermal ablation versus open liver resection for recurrent hepatoblastoma: a retrospective study

Chen

Han

Ling

et al. 2021

International Journal of Hyperthermia

View full text Add to dashboard Cite

Background: The survival of children with recurrent hepatoblastoma (RHB) is still unsatisfactory and the treatment for relapsed patients is challenging. Purpose: To compare short-term results between open liver resection (OLR) and percutaneous thermal ablation (TA) in the treatment of RHB and provide evidence to support the treatment options for such patients. Methods: A retrospective data of 21 patients with RHB in two Chinese centers were analyzed from January 2013 to May 2019. The baseline indicators and clinical effect of the two groups of children were compared.Results: There was no statistical difference in baseline indicators between the two groups of children, and complete remission (CR) was achieved after comprehensive treatment. The median follow-up time was 30 months (IQR 38.5 months) in the TA group, and 23 months (IQR 21.7 months) in OLR group (p ¼ .57). The 2-year OS rates were 92.3% in the percutaneous TA group and 87.5% in the OLR group (p ¼ .68, HR ¼ 1.6, 95% confidence interval [CI]: 0.2-12.4). The 2-year EFS rates were 66.7%, in the TA group and 50.0% in the OLR group (p ¼ .51, HR ¼ 0.6, 95% CI: 0.2-2.6). Compared with the OLR group, TA group had shorter operation time (3.5 ± 1.8 vs. 0.5 ± 0.1, p < .001) and postoperative hospitalization time (11.8 ± 3.0 vs. 9.5 ± 6.8 d, p ¼ .045). No major complications occurred in both groups. Conclusions: Ultrasound-guided percutaneous TA for RHB is a safe and effect treatment option for children. It has comparable effect with surgery within 2 years after treatment. Particularly, due to its minimally invasive advantage, it needs shorter operation and hospitalization time. Percutaneous ablation may be an alternative minimally invasive treatment for RHB children.

show abstract

“…A cross-sectional study Metastectomy and new minimally invasive procedures performed by the interventional radiologist are important in salvage treatment 2 . Radiofrequency Ablation (RA) and Transarterial Chemoembolization (TACE) are examples of treatments that help control symptoms and reduce lesion size 2,9,17,18 . These techniques are already used as bridge therapy for adult patients and, though still not widespread for pediatric ones, should be considered.…”

Section: Rev Col Bras Cir 49:e20223273mentioning

confidence: 99%

Primary Malignant Liver Tumors: eight-year experience in a Pediatric Hospital in Brazil. A cross-sectional study

Falqueto¹,

Vilar²,

Campos³

et al. 2022

Rev. Col. Bras. Cir.

View full text Add to dashboard Cite

Introduction: liver tumors are rare neoplasms in childhood (1-2%), and about 2/3 are malignant. Hepatoblastoma (HB) is the most frequent, followed by hepatocellular carcinoma (HCC). In both, the main treatment is surgical resection. Currently, chemotherapy and liver transplantation have improved outcomes. Objective: study of the epidemiological profile and evolution of liver cancer cases in a referral pediatric hospital. Methodology: a retrospective survey of medical records of patients aged up to 18 years with a diagnosis of primary malignant hepatic neoplasm between 2012 and 2020, carried out in the largest exclusively pediatric hospital in Brazil. Results: a total of 13 patients with malignant liver tumors (HB 12, HCC 1) were treated. Of the HB cases, 66,7% were male, with a mean age of 2 years and the main alteration in the palpable abdominal mass. Tumors involved an average of 3 liver segments, more in the right lobe (54%). Only one patient was treated with surgery without neoadjuvant therapy, another one underwent transplantation like the first treatment, and another 2 required liver transplantation as a rescue. The middle follow-up time of patients with HB was 39 months and only 1 case died due to febrile neutropenia. The 5-year overall and disease-free survival was 91.7% and 81.5%, respectively. Conclusion: Advanced staging at the time of diagnosis has always been a poor prognostic factor in patients with primary malignant liver tumors. However, the results and survival have improved with the advancement of chemotherapy, surgical technique, and liver transplantation.

show abstract

Stereotactic radiofrequency ablation of a variety of liver masses in children

Cited by 13 publications

References 39 publications

Radiofrequency Ablation for Pediatric Recurrent Hepatocellular Carcinoma: A Single-center Experience

Radiofrequency Ablation for Pediatric Recurrent Hepatocellular Carcinoma: A Single-center Experience

Percutaneous thermal ablation versus open liver resection for recurrent hepatoblastoma: a retrospective study

Primary Malignant Liver Tumors: eight-year experience in a Pediatric Hospital in Brazil. A cross-sectional study

Contact Info

Product

Resources

About